Research Article
The Role of Radiotherapy for Patients with Unresectable Locally Advanced Breast Cancer following Neoadjuvant Systemic Therapy
Table 2
Treatment summary of DRT and NART subgroups.
| | Parameters | Total (n = 71) | DRT (n = 45) | NART (n = 26) | | | No. (%) | No. (%) | No. (%) |
| | Neoadjuvant treatment | | Chemotherapy | 70 (98.6) | 44 (97.8) | 26 (100) | 0.444 | | Median no. of lines of chemotherapy (range) | 2 (1–4) | 1 (1–4) | 2 (1–3) | — | | Median no. of cycles of chemotherapy (range) | 8 (2–27) | 8 (2–27) | 7 (2–14) | — | | Endocrine therapy | 5 (7.0) | 4 (8.9) | 1 (3.8) | 0.424 | | HER2-targeted therapy | 20 (28.2) | 13 (28.9) | 7 (26.9) | 0.859 |
| | Radiation treatment | | Median dose (Gy) (range) | 50 (30–56) | 50 (30–56) | 50 (46–50) | — | | Median no. of fractions (range) | 25 (10–28) | 25 (15–28) | 25 (23–25) | — | | Boost to tumor bed/regional nodes | 43 (60.6) | 35 (77.8) | 8 (30.8) | <0.001 | | Median boost dose (Gy) (range) | 14 (6–20) | 14 (10–20) | 13 (6–20) | — | | Median no. of boost fractions (range) | 7 (3–10) | 7 (5–10) | 6.5 (3–10) | — | | Fractionation schemes | <0.001 | | 45 Gy/15 Fx | 1 (1.4) | 1 (2.2) | 0 (0.0) | | 46–50 Gy/23–25 Fx | 28 (39.4) | 10 (22.2) | 18 (69.2) | | 56–70 Gy/28–35 Fx | 42 (59.2) | 34 (75.6) | 8 (30.8) | | Concurrent chemotherapy | 40 (56.3) | 24 (53.3) | 16 (61.5) | 0.502 | | Cisplatin | 19 (26.8) | 9 (20.0) | 10 (38.5) | 0.197 | | Capecitabine | 17 (23.9) | 11 (24.4) | 6 (23.1) | | Taxane-based | 4 (5.6) | 4 (8.9) | (0.0) |
| | Surgery | | MRM | 20 (28.2) | — | 20 (76.9) | — | | MRM + reconstruction | 5 (7.0) | — | 5 (19.2) | | | BCS + ALND | 1 (1.4) | — | 1 (3.8) | |
|
|
DRT = definitive radiotherapy; NART = neoadjuvant radiotherapy; MRM = mastectomy; BCS = breast-conserving surgery; ALND = axillary lymph node dissection.
|
